Biogen Pharmachem Industries Limited has formally notified the stock exchange about an upcoming board meeting to consider the declaration of bonus shares. The meeting represents a significant corporate development that could benefit existing shareholders through additional equity allocation.

Board Meeting Details

The company has scheduled the board meeting with specific parameters and regulatory compliance requirements:

Regulatory Compliance and Approval Process

The bonus share declaration falls under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized that the proposed bonus share issuance will be implemented in accordance with applicable provisions and remains subject to shareholder approval.

The formal intimation was communicated to BSE Limited, where the company trades under scrip code 531752. Wholetime Director Kelash Bunkar signed the official notification, ensuring proper corporate governance protocols are followed.

Company Information

Biogen Pharmachem Industries Limited operates with CIN number L51100GJ1995PLC026702, indicating its incorporation in Gujarat in 1995. The company maintains its registered office at Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001.

The bonus share consideration represents a potential value addition for existing shareholders, as such declarations typically indicate the company's confidence in its financial position and future prospects. However, the final decision will depend on board deliberations and subsequent shareholder approval through the prescribed corporate governance process.

Biogen Pharmachem Industries Limited has announced a board meeting scheduled for February 3, 2026, to consider its Q3FY26 unaudited financial results. The company has formally notified BSE Limited about this meeting in compliance with regulatory requirements.

Board Meeting Details

The meeting agenda and key details are outlined below:

Meeting Agenda

The board will consider the following matters during the scheduled meeting:

• Approval and recording of unaudited financial results for the quarter and nine months ended December 31, 2025
• Any other business matters that the board may deem appropriate with necessary permissions

Regulatory Compliance

Biogen Pharmachem Industries Limited has issued this intimation pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was formally communicated to BSE Limited, where the company's shares are listed under scrip code 531752 and scrip ID BIOGEN.

Company Information

The company, formerly known as Sun Techno Overseas Limited, operates under CIN number L51100GJ1995PLC026702. Director Kelash Bunkar signed the official communication to the stock exchange on January 19, 2026, ensuring compliance with mandatory disclosure requirements for listed companies.